Successful interferon desensitization in a patient with chronic hepatitis C infection

World Journal of Gastroenterology

Volumn 15, Issue 33, 2009, Pages 4196-4198

  Taghavi, Seyed Alireza ^a   Eshraghian, Ahad ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chronic hepatitis C; Desensitization; Drug hypersensitivity; Interferon a2b; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA2B INTERFERON; ASPARTATE AMINOTRANSFERASE; COMPLEMENTARY DNA; DIPHENHYDRAMINE; HEPATITIS C ANTIBODY; PDFERON; RIBAVIRIN; UNCLASSIFIED DRUG; ANTIVIRUS AGENT;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; DESENSITIZATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; ERADICATION THERAPY; FATIGUE; FEVER; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HEPATOMEGALY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIVER BIOPSY; LIVER FIBROSIS; MACULOPAPULAR RASH; MALE; MORNING DOSAGE; PHYSICAL EXAMINATION; PRURITUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; VIRUS DETECTION;

AGED; ANTIVIRAL AGENTS; DRUG HYPERSENSITIVITY; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE;

EID: 70449698088     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.4196     Document Type: Article

References (10)

1. Willems M, Metselaar HJ, Tilanus HW, Schalm SW, de Man RA. Liver transplantation and hepatitis C. Transpl Int 2002; 15: 61-72
2. Alberti A, Benvegnù L. Management of hepatitis C. J Hepatol 2003; 38 Suppl 1: S104-S118
3. Donahue JG, Muñoz A, Ness PM, Brown DE Jr, Yawn DH, McAllister HA Jr, Reitz BA, Nelson KE. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 1992; 327: 369-373
4. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26: 62S-65S
5. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling MH, Albrecht J. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1493-1499
6. Saracco G, Ciancio A, Olivero A, Smedile A, Roffi L, Croce G, Colletta C, Cariti G, Andreoni M, Biglino A, Calleri G, Maggi G, Tappero GF, Orsi PG, Terreni N, Macor A, Di Napoli A, Rinaldi E, Ciccone G, Rizzetto M. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone. Hepatology 2001; 34: 133-138
7. Alavian SM, Einollahi B, Hajarizadeh B, Bakhtiari S, Nafar M, Ahrabi S. Prevalence of hepatitis C virus infection and related risk factors among Iranian haemodialysis patients. Nephrology (Carlton) 2003; 8: 256-260 (Pubitemid 37430951)
8. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008; 48: 148-162 (Pubitemid 350191999)
9. Samimi-Rad K, Nategh R, Malekzadeh R, Norder H, Magnius L. Molecular epidemiology of hepatitis C virus in Iran as reflected by phylogenetic analysis of the NS5B region. J Med Virol 2004; 74: 246-252 (Pubitemid 39150391)
10. Gammon D, Bhargava P, McCormick MJ. Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol. Oncologist 2004; 9: 546-549 (Pubitemid 39332318)